Columbia Researchers Linked Inflammation to PANS, PANDAS
A study published August 11, 2026, revealed inflammatory processes affecting the blood-brain barrier in these disorders.
Updated on Sept. 22, 2026 in Autism
Live Poll
Do you trust that current medical research accurately identifies the physical causes of complex childhood syndromes?
Researchers at Columbia University Irving Medical Center identified that cytokine IL-17A plays a critical role in blood-brain barrier dysfunction associated with PANS and PANDAS. The findings, published August 11, 2026, detail how Group A Streptococcus infections trigger inflammatory changes in the brain.
Why it matters
This research provides a biological framework to explain the immune-mediated origins of complex neurological symptoms in children. By mapping these inflammatory pathways, the study offers a foundation for better understanding the underlying causes of PANS and PANDAS.
Researchers identified upregulated blood markers in 23 acutely sick children that may track disease progression. This discovery builds on 15 years of work investigating these immune-mediated neurological conditions.
The players
Dr. Agalliu
A researcher who has spent 15 years studying the mechanisms behind PANS and PANDAS disorders.
Columbia University Irving Medical Center
An academic medical center in New York City where the research study was conducted.
The details
The study utilized mouse genetic models and single-cell RNA sequencing to demonstrate that Group A Streptococcus infections induce inflammatory gene changes in brain microglia and endothelial cells. By eliminating inflammatory cytokines produced by T lymphocytes, the team successfully isolated the role of IL-17A in damaging the blood-brain barrier.
Timeline
In 2016, Dr. Agalliu identified GAS-induced T lymphocyte migration.
In 2020, researchers demonstrated that Th17 lymphocytes trigger brain pathology.
The research paper was published in Nature Communications on August 11, 2026.
The study findings were publicly announced on September 22, 2026.
The Big Picture
This research follows the trajectory of the Columbia University Irving Medical Center immune-mediated neurology research program. The discovery of the IL-17A pathway provides a specific molecular target that builds upon years of research into brain inflammation.
This research offers families a more concrete understanding of the biological mechanisms driving their children's symptoms. While currently focused on discovery, these insights provide a path toward identifying future diagnostic markers and targeted treatments for patients.
The takeaway
Understanding the role of IL-17A in blood-brain barrier dysfunction marks a significant shift toward viewing these disorders through a precise immunological lens. This study emphasizes the importance of continued research into the intersection of infection and neurodevelopmental health.
What happens next
Future studies are planned to identify the downstream effectors of IL-17A/IL-17RA signaling and to define the specific genetic risk factors that underlie susceptibility to PANS and PANDAS.
Further reading
For additional context on immune-related neurodevelopmental studies, visit Autism.
More information
To support ongoing investigation into these conditions, you can donate to support additional research.
Source note: This article includes information reported by Adnkronos.
Live Poll
Do you trust that current medical research accurately identifies the physical causes of complex childhood syndromes?
